ACADIA Pharmaceuticals Inc.
ACAD
Helyezés a részvények között
#4516
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Részvényárfolyam
$19.76
Utolsó szinkronizálás: 2026-10-19
Piaci kapitalizáció
$3.40B
Változás (1 nap)
3.32%
Változás (1 év)
-5.66%
Ország
US
Kereskedés ACADIA Pharmaceuticals Inc. (ACAD)
Kategória
Healthcare
EPS ACADIA Pharmaceuticals Inc. (ACAD) részvényre
EPS June 2026 dátummal, TTM: $2.25
ACADIA Pharmaceuticals Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $2.25. 2023 végén a vállalat EPS mutatója $-0.37 volt, csökkenés a 2022 év EPS értékéhez, amely $-1.34 volt.
ACADIA Pharmaceuticals Inc. EPS története 2000 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $2.25 | 64.23% |
| 2024 | $1.37 | -470.27% |
| 2023 | $-0.37 | -72.39% |
| 2022 | $-1.34 | 27.62% |
| 2021 | $-1.05 | -41.34% |
| 2020 | $-1.79 | 11.88% |
| 2019 | $-1.60 | -17.53% |
| 2018 | $-1.94 | -17.80% |
| 2017 | $-2.36 | 0.85% |
| 2016 | $-2.34 | 43.56% |
| 2015 | $-1.63 | 71.58% |
| 2014 | $-0.95 | 115.91% |
| 2013 | $-0.44 | 15.79% |
| 2012 | $-0.38 | -13.64% |
| 2011 | $-0.44 | -212.82% |
| 2010 | $0.39 | -132.50% |
| 2009 | $-1.20 | -30.64% |
| 2008 | $-1.73 | 8.12% |
| 2007 | $-1.60 | -0.62% |
| 2006 | $-1.61 | 3.87% |
| 2005 | $-1.55 | -38.00% |
| 2004 | $-2.50 | -74.12% |
| 2003 | $-9.66 | 9.03% |
| 2002 | $-8.86 | -25.73% |
| 2001 | $-11.93 | 25.18% |
| 2000 | $-9.53 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | 669.78% |
US
|
|
| $-7.98 | -454.67% |
US
|
|
| $-5.29 | -335.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,132.89% |
NL
|
